Literature DB >> 22017583

The pathogenesis of mixed-lineage leukemia.

Andrew G Muntean1, Jay L Hess.   

Abstract

Aggressive leukemias arise in both children and adults as a result of rearrangements to the mixed-lineage leukemia gene (MLL) located on chromosome 11q23. MLL encodes a large histone methyltransferase that directly binds DNA and positively regulates gene transcription, including homeobox (HOX) genes. MLL is involved in chromosomal translocations, partial tandem duplications, and amplifications, all of which result in hematopoietic malignancies due to sustained HOX expression and stalled differentiation. MLL lesions are associated with both acute myeloid leukemia and acute lymphoid leukemia and are usually associated with a relatively poor prognosis despite improved treatment options such as allogeneic hematopoietic stem cell transplantation, which underscores the need for new treatment regimens. Recent advances have begun to reveal the molecular mechanisms that drive MLL-associated leukemias, which, in turn, have provided opportunities for therapeutic development. Here, we discuss the etiology of MLL leukemias and potential directions for future therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017583      PMCID: PMC3381338          DOI: 10.1146/annurev-pathol-011811-132434

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  109 in total

1.  MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein.

Authors:  P Ernst; J Wang; M Huang; R H Goodman; S J Korsmeyer
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.

Authors:  Marco Birke; Silke Schreiner; María-Paz García-Cuéllar; Kerstin Mahr; Fritz Titgemeyer; Robert K Slany
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

3.  The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation.

Authors:  Nevan J Krogan; Jim Dover; Adam Wood; Jessica Schneider; Jonathan Heidt; Marry Ann Boateng; Kimberly Dean; Owen W Ryan; Ashkan Golshani; Mark Johnston; Jack F Greenblatt; Ali Shilatifard
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

4.  ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation.

Authors:  Tatsuya Nakamura; Toshiki Mori; Shinichiro Tada; Wladyslaw Krajewski; Tanya Rozovskaia; Richard Wassell; Garrett Dubois; Alexander Mazo; Carlo M Croce; Eli Canaani
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

5.  Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization.

Authors:  James J-D Hsieh; Patricia Ernst; Hediye Erdjument-Bromage; Paul Tempst; Stanley J Korsmeyer
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

6.  Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality.

Authors:  T Rozovskaia; E Feinstein; O Mor; R Foa; J Blechman; T Nakamura; C M Croce; G Cimino; E Canaani
Journal:  Oncogene       Date:  2001-02-15       Impact factor: 9.867

7.  MLL targets SET domain methyltransferase activity to Hox gene promoters.

Authors:  Thomas A Milne; Scott D Briggs; Hugh W Brock; Mary Ellen Martin; Denise Gibbs; C David Allis; Jay L Hess
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

8.  Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6.

Authors:  Jim Dover; Jessica Schneider; Mary Anne Tawiah-Boateng; Adam Wood; Kimberly Dean; Mark Johnston; Ali Shilatifard
Journal:  J Biol Chem       Date:  2002-06-17       Impact factor: 5.157

9.  Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.

Authors:  Christine Steudel; Martin Wermke; Markus Schaich; Ulrike Schäkel; Thomas Illmer; Gerhard Ehninger; Christian Thiede
Journal:  Genes Chromosomes Cancer       Date:  2003-07       Impact factor: 5.006

10.  Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.

Authors:  Adolfo A Ferrando; Scott A Armstrong; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman; Stanley J Korsmeyer; A Thomas Look
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

View more
  156 in total

1.  Deregulation of HOX genes by DNMT3A and MLL mutations converges on BMI1.

Authors:  Y-T Tan; Y Sun; S-H Zhu; L Ye; C-J Zhao; W-L Zhao; Z Chen; S-J Chen; H Liu
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

Review 2.  Histone methyltransferase and histone methylation in inflammatory T-cell responses.

Authors:  Shan He; Qing Tong; Dennis Keith Bishop; Yi Zhang
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

3.  Trithorax and polycomb cooperation in MLL fusion acute leukemia.

Authors:  Helene Méreau; Juerg Schwaller
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

Review 4.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

5.  Targeting acute myeloid leukemia by drug-induced c-MYB degradation.

Authors:  V Walf-Vorderwülbecke; K Pearce; T Brooks; M Hubank; M M van den Heuvel-Eibrink; C M Zwaan; S Adams; D Edwards; J Bartram; S Samarasinghe; P Ancliff; A Khwaja; N Goulden; G Williams; J de Boer; O Williams
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

6.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Authors:  Eytan M Stein; Guillermo Garcia-Manero; David A Rizzieri; Raoul Tibes; Jesus G Berdeja; Michael R Savona; Mojca Jongen-Lavrenic; Jessica K Altman; Blythe Thomson; Stephen J Blakemore; Scott R Daigle; Nigel J Waters; A Benjamin Suttle; Alicia Clawson; Roy Pollock; Andrei Krivtsov; Scott A Armstrong; Jorge DiMartino; Eric Hedrick; Bob Löwenberg; Martin S Tallman
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

7.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Authors:  Wenyu Yu; Emma J Chory; Amy K Wernimont; Wolfram Tempel; Alex Scopton; Alexander Federation; Jason J Marineau; Jun Qi; Dalia Barsyte-Lovejoy; Joanna Yi; Richard Marcellus; Roxana E Iacob; John R Engen; Carly Griffin; Ahmed Aman; Erno Wienholds; Fengling Li; Javier Pineda; Guillermina Estiu; Tatiana Shatseva; Taraneh Hajian; Rima Al-Awar; John E Dick; Masoud Vedadi; Peter J Brown; Cheryl H Arrowsmith; James E Bradner; Matthieu Schapira
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

8.  DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.

Authors:  Li-Lun Ho; Amit Sinha; Michael Verzi; Kathrin M Bernt; Scott A Armstrong; Ramesh A Shivdasani
Journal:  Mol Cell Biol       Date:  2013-02-19       Impact factor: 4.272

9.  Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution.

Authors:  Nuno Cerveira; Susana Lisboa; Cecília Correia; Susana Bizarro; Joana Santos; Lurdes Torres; Joana Vieira; João D Barros-Silva; Dulcineia Pereira; Cláudia Moreira; Claus Meyer; Tereza Oliva; Ilídia Moreira; Ângelo Martins; Luísa Viterbo; Vítor Costa; Rolf Marschalek; Armando Pinto; José M Mariz; Manuel R Teixeira
Journal:  Mol Oncol       Date:  2012-07-14       Impact factor: 6.603

10.  Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.

Authors:  Nilda L Alicea-Velázquez; Stephen A Shinsky; Daniel M Loh; Jeong-Heon Lee; David G Skalnik; Michael S Cosgrove
Journal:  J Biol Chem       Date:  2016-08-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.